Abstract: Apparatus and methods for equalization are provided. In certain implementations, an equalizer includes first and second feedback resistors, first and second equalization resistors, an equalization capacitor, and an amplification circuit that includes first to fourth input terminals and first and second output terminals. The amplification circuit can receive a differential input voltage signal between the first and third input terminals, and the first and second equalization resistors and the equalization capacitor are electrically connected in series between the second and fourth input terminals with the equalization capacitor between the first and second equalization resistors. Additionally, the first feedback resistor is electrically connected between the first output terminal and the second input terminal, and the second feedback resistor is electrically connected between the second output terminal and the fourth input terminal.

Abstract: The present invention provides carbamylation compositions of one or more urea compounds, one or more polyols and a monovalent transition metal or alkali metal catalyst (i), such as lithium ethylhexanoate, which compositions are substantially isocyanate free, enjoy reduced toxicity in comparison to tin catalysts, and which are useful in making polycarbamates which themselves provide compositions for making crosslinked polyurethanes.

Abstract: The instant invention provides a crosslinkable coating composition, and method of producing the same. The crosslinkable coating composition according to the present invention comprises: (a) one or more polycarbamates derived from one or more polyesters comprising the condensation reaction product of one or more polyols with one or more polyacids, wherein said one or more polyols comprise at least 25 percent by weight of one or more units having 4 or more hydroxyl groups; (b) one or more crosslinking agents; (c) one or more acid catalysts; and (d) optionally one or more organic solvents.

Abstract: A method for providing live and archived cycling classes to remote users comprising providing information about available live and archived cycling classes that can be accessed via a digital communication network by a first user using a first stationary bike at a first remote location for display at the first remote location via an interface that includes a display screen, whereby the first user can select either a live cycling class or select among a plurality of archived cycling classes to be displayed on the display screen, receiving from the first user a selection of one of the available live or archived cycling classes for display on the display screen at the first remote location, and providing digital video and audio content comprising the selected cycling class to a computer at the first remote location for display to the first user.

Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.

Abstract: A method for providing cycling classes to remote users comprising providing information about available cycling classes that can be accessed via a digital communication network by a user at a remote location for display at the remote location, receiving from the user a selection of one of the available cycling classes for display at the remote location, and sending digital video and audio content comprising the selected cycling class from a server to a computer associated with a stationary bike at the remote location for display to the user on a display screen associated with the stationary bike. In various exemplary embodiments, the digital and audio content sent to the computer associated with the stationary bike is streamed for display to the user in substantially in real-time. In various exemplary embodiments, the digital and audio content sent to the computer associated with the stationary bike is archived content provided from a database.

Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.

Abstract: The instant invention provides crosslinkable compositions, and method of producing the same. The non-aqueous single phase crosslinkable composition comprises: (a) a polyol having an average of 2 or more hydroxyl functional groups; (b) polyaldehyde, or acetal or hemiacetal thereof; and (c) an acid catalyst having pK of less than 6; and (d) optionally one or more organic solvents.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: The instant invention provides a crosslinkable aqueous composition, method of producing the same, crosslinked compositions, and method of producing the same. The crosslinkable composition comprising: an aqueous dispersion comprising; (a) water; (b) a polycarbamate comprising at least an average of 2.0 carbamate functional groups; (c) a polyaldehyde comprising at least two aldehyde groups; (d) an acid catalyst; and (e) optionally one or more surfactants; wherein said aqueous dispersion has a pH in the range of less than 7; and wherein said composition is capable of being crosslinked at a temperature in range of less than 80° C. upon substantial removal of water.

Abstract: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.

Abstract: The instant invention provides crosslinkable compositions, and method of producing the same. The non-aqueous single phase crosslinkable composition comprises: (a) a polyol having an average of 2 or more hydroxyl functional groups; (b) polyaldehyde, or acetal or hemiacetal thereof; and (c) an acid catalyst having pK of less than 6; and (d) optionally one or more organic solvents.

Abstract: Embodiments of the invention provide for a polycarbonate polyol including the reaction product of at least one polyol composition and a carbonate. The polycarbonate is one of an amorphous liquid and an amorphous solid at room temperature. The polyol composition includes at least one of a mixture of 1,3-cyclohexanedimethanol and 1,4-cyclohexanedimethanol in a weight ratio from about 60:40 to about 5:95 and a polyol derived from a natural oil fatty acid or natural oil fatty acid methyl ester.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.

Abstract: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.

Abstract: A first process to produce polycarbamate comprising providing urea in liquid form; and adding the liquid urea to a polyol is provided. A second process for producing polycarbamate comprising adding solid urea to a polyol in liquid form to form a reaction mixture is provided. Also provided is a reaction product produced by the first process or second process.

Abstract: The instant invention provides crosslinkable compositions, and method of producing the same. The non-aqueous single phase crosslinkable composition comprises: (a) a polyol having an average of 2 or more hydroxyl functional groups; (b) polyaldehyde, or acetal or hemiacetal thereof; and (c) an acid catalyst having pK of less than 6; and (d) optionally one or more organic solvents.